Troglitazone induces GLUT4 translocation in L6 myotubes

Shin Yonemitsu, Haruo Nishimura, Mitsuyo Shintani, Ryou Inoue, Yuji Yamamoto, Hiroaki Masuzaki, Yoshihiro Ogawa, Kiminori Hosoda, Gen Inoue, Tatsuya Hayashi, Kazuwa Nakao

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

A number of studies have demonstrated that insulin resistance in the skeletal muscle plays a pivotal role in the insulin resistance associated with obesity and type 2 diabetes. A decrease in GLUT4 translocation from the intracellular pool to the plasma membranes in skeletal muscles has been implicated as a possible cause of insulin resistance. Herein, we examined the effects of an insulin-sensitizing drug, troglitazone (TGZ), on glucose uptake and the translocation of GLUT4 in L6 myotubes. The prolonged exposure (24 h) of L6 myotubes to TGZ (10-5 mol/l) caused a substantial increase in the 2-deoxy-[3H]D-glucose (2-DG) uptake without changing the total amount of the glucose transporters GLUT4, GLUT1, and GLUT3. The TGZ-induced 2-DG uptake was completely abolished by cytochalasin-B (10 μmol/l). The ability of TGZ to translocate GLUT4 from light microsomes to the crude plasma membranes was greater than that of insulin. Both cycloheximide treatment (3.5 × 10-6 mol/l) and the removal of TGZ by washing reversed the 2-DG uptake to the basal level. Moreover, insulin did not enhance the TGZ-induced 2-DG uptake additively. The TGZ-induced 2-DG uptake was only partially reversed by wortmannin to 80%, and TGZ did not change the expression and the phosphorylation of protein kinase B; the expression of protein kinase C (PKC)-λ, PKC-β2, and PKC-ξ; or 5′ AMP-activated protein kinase activity. α-Tocopherol, which has a molecular structure similar to that of TGZ, did not increase 2-DG uptake. We conclude that the glucose transport in L6 myotubes exposed to TGZ for 24 h is the result of an increased translocation of GLUT4. The present results imply that the effects of troglitazone on GLUT4 translocation may include a new mechanism for improving glucose transport in skeletal muscle.

Original languageEnglish
Pages (from-to)1093-1101
Number of pages9
JournalDiabetes
Volume50
Issue number5
DOIs
Publication statusPublished - Jan 1 2001

Fingerprint

troglitazone
Skeletal Muscle Fibers
Insulin Resistance
Skeletal Muscle
Insulin
Glucose
Cell Membrane
Proto-Oncogene Proteins c-akt
Cytochalasin B
AMP-Activated Protein Kinases

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Yonemitsu, S., Nishimura, H., Shintani, M., Inoue, R., Yamamoto, Y., Masuzaki, H., ... Nakao, K. (2001). Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes, 50(5), 1093-1101. https://doi.org/10.2337/diabetes.50.5.1093

Troglitazone induces GLUT4 translocation in L6 myotubes. / Yonemitsu, Shin; Nishimura, Haruo; Shintani, Mitsuyo; Inoue, Ryou; Yamamoto, Yuji; Masuzaki, Hiroaki; Ogawa, Yoshihiro; Hosoda, Kiminori; Inoue, Gen; Hayashi, Tatsuya; Nakao, Kazuwa.

In: Diabetes, Vol. 50, No. 5, 01.01.2001, p. 1093-1101.

Research output: Contribution to journalArticle

Yonemitsu, S, Nishimura, H, Shintani, M, Inoue, R, Yamamoto, Y, Masuzaki, H, Ogawa, Y, Hosoda, K, Inoue, G, Hayashi, T & Nakao, K 2001, 'Troglitazone induces GLUT4 translocation in L6 myotubes', Diabetes, vol. 50, no. 5, pp. 1093-1101. https://doi.org/10.2337/diabetes.50.5.1093
Yonemitsu S, Nishimura H, Shintani M, Inoue R, Yamamoto Y, Masuzaki H et al. Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes. 2001 Jan 1;50(5):1093-1101. https://doi.org/10.2337/diabetes.50.5.1093
Yonemitsu, Shin ; Nishimura, Haruo ; Shintani, Mitsuyo ; Inoue, Ryou ; Yamamoto, Yuji ; Masuzaki, Hiroaki ; Ogawa, Yoshihiro ; Hosoda, Kiminori ; Inoue, Gen ; Hayashi, Tatsuya ; Nakao, Kazuwa. / Troglitazone induces GLUT4 translocation in L6 myotubes. In: Diabetes. 2001 ; Vol. 50, No. 5. pp. 1093-1101.
@article{8cc2ca0693ea43349b497d41ec99a942,
title = "Troglitazone induces GLUT4 translocation in L6 myotubes",
abstract = "A number of studies have demonstrated that insulin resistance in the skeletal muscle plays a pivotal role in the insulin resistance associated with obesity and type 2 diabetes. A decrease in GLUT4 translocation from the intracellular pool to the plasma membranes in skeletal muscles has been implicated as a possible cause of insulin resistance. Herein, we examined the effects of an insulin-sensitizing drug, troglitazone (TGZ), on glucose uptake and the translocation of GLUT4 in L6 myotubes. The prolonged exposure (24 h) of L6 myotubes to TGZ (10-5 mol/l) caused a substantial increase in the 2-deoxy-[3H]D-glucose (2-DG) uptake without changing the total amount of the glucose transporters GLUT4, GLUT1, and GLUT3. The TGZ-induced 2-DG uptake was completely abolished by cytochalasin-B (10 μmol/l). The ability of TGZ to translocate GLUT4 from light microsomes to the crude plasma membranes was greater than that of insulin. Both cycloheximide treatment (3.5 × 10-6 mol/l) and the removal of TGZ by washing reversed the 2-DG uptake to the basal level. Moreover, insulin did not enhance the TGZ-induced 2-DG uptake additively. The TGZ-induced 2-DG uptake was only partially reversed by wortmannin to 80{\%}, and TGZ did not change the expression and the phosphorylation of protein kinase B; the expression of protein kinase C (PKC)-λ, PKC-β2, and PKC-ξ; or 5′ AMP-activated protein kinase activity. α-Tocopherol, which has a molecular structure similar to that of TGZ, did not increase 2-DG uptake. We conclude that the glucose transport in L6 myotubes exposed to TGZ for 24 h is the result of an increased translocation of GLUT4. The present results imply that the effects of troglitazone on GLUT4 translocation may include a new mechanism for improving glucose transport in skeletal muscle.",
author = "Shin Yonemitsu and Haruo Nishimura and Mitsuyo Shintani and Ryou Inoue and Yuji Yamamoto and Hiroaki Masuzaki and Yoshihiro Ogawa and Kiminori Hosoda and Gen Inoue and Tatsuya Hayashi and Kazuwa Nakao",
year = "2001",
month = "1",
day = "1",
doi = "10.2337/diabetes.50.5.1093",
language = "English",
volume = "50",
pages = "1093--1101",
journal = "Diabetes",
issn = "0012-1797",
publisher = "医学出版",
number = "5",

}

TY - JOUR

T1 - Troglitazone induces GLUT4 translocation in L6 myotubes

AU - Yonemitsu, Shin

AU - Nishimura, Haruo

AU - Shintani, Mitsuyo

AU - Inoue, Ryou

AU - Yamamoto, Yuji

AU - Masuzaki, Hiroaki

AU - Ogawa, Yoshihiro

AU - Hosoda, Kiminori

AU - Inoue, Gen

AU - Hayashi, Tatsuya

AU - Nakao, Kazuwa

PY - 2001/1/1

Y1 - 2001/1/1

N2 - A number of studies have demonstrated that insulin resistance in the skeletal muscle plays a pivotal role in the insulin resistance associated with obesity and type 2 diabetes. A decrease in GLUT4 translocation from the intracellular pool to the plasma membranes in skeletal muscles has been implicated as a possible cause of insulin resistance. Herein, we examined the effects of an insulin-sensitizing drug, troglitazone (TGZ), on glucose uptake and the translocation of GLUT4 in L6 myotubes. The prolonged exposure (24 h) of L6 myotubes to TGZ (10-5 mol/l) caused a substantial increase in the 2-deoxy-[3H]D-glucose (2-DG) uptake without changing the total amount of the glucose transporters GLUT4, GLUT1, and GLUT3. The TGZ-induced 2-DG uptake was completely abolished by cytochalasin-B (10 μmol/l). The ability of TGZ to translocate GLUT4 from light microsomes to the crude plasma membranes was greater than that of insulin. Both cycloheximide treatment (3.5 × 10-6 mol/l) and the removal of TGZ by washing reversed the 2-DG uptake to the basal level. Moreover, insulin did not enhance the TGZ-induced 2-DG uptake additively. The TGZ-induced 2-DG uptake was only partially reversed by wortmannin to 80%, and TGZ did not change the expression and the phosphorylation of protein kinase B; the expression of protein kinase C (PKC)-λ, PKC-β2, and PKC-ξ; or 5′ AMP-activated protein kinase activity. α-Tocopherol, which has a molecular structure similar to that of TGZ, did not increase 2-DG uptake. We conclude that the glucose transport in L6 myotubes exposed to TGZ for 24 h is the result of an increased translocation of GLUT4. The present results imply that the effects of troglitazone on GLUT4 translocation may include a new mechanism for improving glucose transport in skeletal muscle.

AB - A number of studies have demonstrated that insulin resistance in the skeletal muscle plays a pivotal role in the insulin resistance associated with obesity and type 2 diabetes. A decrease in GLUT4 translocation from the intracellular pool to the plasma membranes in skeletal muscles has been implicated as a possible cause of insulin resistance. Herein, we examined the effects of an insulin-sensitizing drug, troglitazone (TGZ), on glucose uptake and the translocation of GLUT4 in L6 myotubes. The prolonged exposure (24 h) of L6 myotubes to TGZ (10-5 mol/l) caused a substantial increase in the 2-deoxy-[3H]D-glucose (2-DG) uptake without changing the total amount of the glucose transporters GLUT4, GLUT1, and GLUT3. The TGZ-induced 2-DG uptake was completely abolished by cytochalasin-B (10 μmol/l). The ability of TGZ to translocate GLUT4 from light microsomes to the crude plasma membranes was greater than that of insulin. Both cycloheximide treatment (3.5 × 10-6 mol/l) and the removal of TGZ by washing reversed the 2-DG uptake to the basal level. Moreover, insulin did not enhance the TGZ-induced 2-DG uptake additively. The TGZ-induced 2-DG uptake was only partially reversed by wortmannin to 80%, and TGZ did not change the expression and the phosphorylation of protein kinase B; the expression of protein kinase C (PKC)-λ, PKC-β2, and PKC-ξ; or 5′ AMP-activated protein kinase activity. α-Tocopherol, which has a molecular structure similar to that of TGZ, did not increase 2-DG uptake. We conclude that the glucose transport in L6 myotubes exposed to TGZ for 24 h is the result of an increased translocation of GLUT4. The present results imply that the effects of troglitazone on GLUT4 translocation may include a new mechanism for improving glucose transport in skeletal muscle.

UR - http://www.scopus.com/inward/record.url?scp=0035029808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035029808&partnerID=8YFLogxK

U2 - 10.2337/diabetes.50.5.1093

DO - 10.2337/diabetes.50.5.1093

M3 - Article

C2 - 11334413

AN - SCOPUS:0035029808

VL - 50

SP - 1093

EP - 1101

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 5

ER -